Aimovig® (erenumab) mode of action
This page/content is for Great Britain healthcare professionals only. If you require information for Northern Ireland please refer to the Northern Ireland electronic medicines compendium (emc).
Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.1
Aimovig is specifically designed to stop migraine before it starts2,3
Play the Aimovig mechanism of action video below to see how it is believed to work in migraine.
VIDEO
Aimovig is the first licensed CGRP receptor antagonist in the UK, specifically designed to prevent migraine across the spectrum*1,4
Aimovig is 100% human and binds potently and selectively to the CGRP receptor, blocking its activation1
Your guide to Aimovig
Your guide to Aimovig
A guide for patients prescribed Aimovig to provide them with important information about what Aimovig is, who it is for, how it works and what to expect during treatment.
CGRP, calcitonin gene related peptide; Ig, immunoglobulin.
References
Aimovig® (erenumab) Summary of Product Characteristics.
Aimovig Core Data Sheet v2.5.
Garg S, et al. Anaesthesiology 2020;36(1):104–109.
Bigal ME, et al. Headache 2013;53(8):1230–1244.
UK | October 2024 | FA-11214757
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
